ChemPartner PharmaTech Co Ltd (300149) - Total Assets
Based on the latest financial reports, ChemPartner PharmaTech Co Ltd (300149) holds total assets worth CN¥2.04 Billion CNY (≈ $298.52 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of ChemPartner PharmaTech Co Ltd for net asset value and shareholders' equity analysis.
ChemPartner PharmaTech Co Ltd - Total Assets Trend (2007–2025)
This chart illustrates how ChemPartner PharmaTech Co Ltd's total assets have evolved over time, based on quarterly financial data.
ChemPartner PharmaTech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
ChemPartner PharmaTech Co Ltd's total assets of CN¥2.04 Billion consist of 37.6% current assets and 62.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.3% |
| Accounts Receivable | CN¥229.26 Million | 11.3% |
| Inventory | CN¥9.47 Million | 0.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥32.69 Million | 1.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how ChemPartner PharmaTech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300149 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ChemPartner PharmaTech Co Ltd's current assets represent 37.6% of total assets in 2025, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 20.3% of total assets in 2025, down from 33.4% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 4.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 11.3% of total assets.
ChemPartner PharmaTech Co Ltd Competitors by Total Assets
Key competitors of ChemPartner PharmaTech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
ChemPartner PharmaTech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 1.94 | 1.12 |
| Quick Ratio | 2.09 | 1.89 | 1.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥419.25 Million | CN¥312.20 Million | CN¥102.30 Million |
ChemPartner PharmaTech Co Ltd - Advanced Valuation Insights
This section examines the relationship between ChemPartner PharmaTech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.90 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | CN¥2.03 Billion |
| Market Capitalization | $623.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values ChemPartner PharmaTech Co Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ChemPartner PharmaTech Co Ltd's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ChemPartner PharmaTech Co Ltd (2007–2025)
The table below shows the annual total assets of ChemPartner PharmaTech Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.03 Billion ≈ $297.48 Million |
+1.86% |
| 2024-12-31 | CN¥2.00 Billion ≈ $292.05 Million |
-18.01% |
| 2023-12-31 | CN¥2.43 Billion ≈ $356.22 Million |
-36.34% |
| 2022-12-31 | CN¥3.82 Billion ≈ $559.56 Million |
-9.33% |
| 2021-12-31 | CN¥4.22 Billion ≈ $617.17 Million |
+2.33% |
| 2020-12-31 | CN¥4.12 Billion ≈ $603.12 Million |
+9.39% |
| 2019-12-31 | CN¥3.77 Billion ≈ $551.34 Million |
+12.55% |
| 2018-12-31 | CN¥3.35 Billion ≈ $489.87 Million |
+220.91% |
| 2017-12-31 | CN¥1.04 Billion ≈ $152.65 Million |
+31.52% |
| 2016-12-31 | CN¥793.16 Million ≈ $116.06 Million |
+4.92% |
| 2015-12-31 | CN¥756.00 Million ≈ $110.63 Million |
+2.01% |
| 2014-12-31 | CN¥741.13 Million ≈ $108.45 Million |
+5.28% |
| 2013-12-31 | CN¥703.99 Million ≈ $103.02 Million |
+5.45% |
| 2012-12-31 | CN¥667.61 Million ≈ $97.69 Million |
+5.33% |
| 2011-12-31 | CN¥633.82 Million ≈ $92.75 Million |
+7.90% |
| 2010-12-31 | CN¥587.42 Million ≈ $85.96 Million |
+330.98% |
| 2009-12-31 | CN¥136.30 Million ≈ $19.94 Million |
+56.79% |
| 2008-12-31 | CN¥86.93 Million ≈ $12.72 Million |
+28.24% |
| 2007-12-31 | CN¥67.79 Million ≈ $9.92 Million |
-- |
About ChemPartner PharmaTech Co Ltd
Chempartner Pharmatech Co., Ltd. engages in the microecological nutrition and healthcare businesses worldwide. The company operates in two segments, Microecological Nutrition and Medical Business; and Pharmaceutical Research and Development Service and Production Outsourcing Business. It offers prebiotic products and the provision of microecological medical services. The company provides comprehe… Read more